Earnings ·
Cabaletta Bio, Inc. reported financial results for the second quarter ended June 30, 2026, showing a net loss of $51.0…
CABACabaletta Bio, Inc.
Cabaletta Bio, Inc. reported financial results for the second quarter ended June 30, 2026, showing a net loss of $51.0 million and R&D expenses of $44.4 million. The company holds approximately $225.1 million in cash, providing runway into mid-2027. Clinically, registrational RESET-Myositis data is on track for mid-2027 to support a BLA submission in the second half of 2027, while a new registrational study for SSc-associated ILD is expected to initiate in the fourth quarter of 2026. The company also expanded its manufacturing supply chain by partnering with ElevateBio as an additional CDMO and announced a 10-year agreement with Cellares for automated production. Cabaletta Bio operates in the biotechnology industry, developing curative targeted cell therapies for autoimmune diseases.